GleamWall
中文EN

CSCIF COSCIENS Biopharma Inc. IFRS

Perfumes, Cosmetics & Other Toilet Preparations · OTC · SEC CIK 1113423 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-21.8%
TTM net income YoY32.3%
TTM EPS YoY44.9%
Revenue 3-yr CAGR-19.9%
Net income 3-yr CAGR—

Margins

Gross margin35.3%
Operating margin-142.5%
Net margin-138.1%
FCF margin-122.4%
EBITDA margin-126.6%

Returns

ROE-121.8%
ROA-36.7%
ROIC (approx.)—
Asset turnover0.27x

Leverage & solvency

Liabilities / assets82.1%
Debt / equity0.00x
Current ratio3.18x
Interest coverage-63.58x

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue9.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q1*2025-03-312024Q4*2024-12-312024Q3*2024-09-302024Q2*2024-06-302024Q1*2024-03-31
Income statement
Revenue$1.77M$1.48M$2.75M$1.50M$3.32M$1.87M$2.34M$2.06M
Cost of revenue$1.16M$862,000$1.77M$1.06M$1.27M$914,000$1.52M$1.15M
Gross profit$609,000$621,000$974,000$443,000$2.05M$957,000$819,000$904,000
R&D expense$599,000$527,000$690,000$1.13M$2.91M$2.80M$1.53M$1.06M
SG&A expense$2.40M$2.10M$2.64M$2.93M$2.75M$2.99M$3.04M$1.66M
Operating income-$2.39M-$2.32M-$2.35M-$3.62M-$6.41M-$6.29M-$3.75M-$1.81M
Interest expense$32,000$43,000$23,000$70,000$23,000$22,000$22,000$63,000
Pretax income-$2.17M-$1.82M-$2.70M-$3.65M-$5.65M-$5.87M-$1.90M-$1.81M
Income tax——$1,000—$1.08M-$112,000-$474,000-$412,000
Net income-$2.18M-$1.82M-$2.70M-$3.65M-$6.73M-$5.75M-$1.42M-$1.40M
EBITDA-$2.10M-$2.04M-$2.07M-$3.29M-$6.02M-$5.81M-$3.38M-$1.46M
EPS (basic)—-0.57-0.85-1.16—-1.85-0.64-0.76
EPS (diluted)—-0.57-0.85-1.16—-1.85-0.64-0.76
Weighted avg. shares (diluted)—3.18M3.17M3.14M—3.11M2.22M1.85M
Balance sheet
Cash & equivalents$7.31M$8.52M$9.33M$13.76M$16.39M$20.00M$27.80M$3.51M
Receivables$1.26M$1.60M$2.78M$1.86M$2.36M$1.89M$1.24M$190,000
Inventory$1.31M$1.76M$1.82M$2.46M$2.69M$3.31M$3.06M$64,000
Current assets$11.50M$13.84M$16.50M$20.35M$23.98M$28.22M$33.21M$31.20M
PP&E, netmay include right-of-use assets (IFRS)$9.81M$9.89M$10.92M$10.66M$10.97M$11.81M$11.50M$271,000
Intangibles—————$1.81M$3.33M—
Total assets$21.43M$23.86M$27.56M$31.14M$35.07M$43.77M$50.05M$31.79M
Current liabilities$3.61M$3.98M$5.53M$7.06M$7.22M$8.17M$9.90M$5.25M
Total liabilities$17.59M$18.78M$20.46M$21.00M$21.91M$23.75M$23.82M$18.82M
Shareholders' equity$3.84M$5.08M$7.10M$10.14M$13.16M$20.01M$26.23M$19.19M
Cash flow statement
Operating cash flow-$1.47M-$676,000-$4.45M-$1.88M-$3.00M-$7.78M-$1.39M-$2.38M
Capital expenditure$46,000-$4,000$49,000$615,000$309,000$131,000$157,000$564,000
Free cash flow-$1.52M-$672,000-$4.50M-$2.50M-$3.31M-$7.91M-$1.55M-$2.94M
Investing cash flow$201,000$4,000-$48,000-$615,000-$316,000$83,000$25.88M-$564,000
Financing cash flow-$15,000-$85,000-$107,000-$200,000-$202,000-$188,000-$126,000-$94,000
Depreciation & amortization$289,000$287,000$287,000$325,000$392,000$479,000$377,000$359,000
Stock-based compensation$88,000-$21,000-$85,000$6,000$10,000$427,000$13,000$14,000

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.